Literature DB >> 19675464

Differential survival benefit of universal HAART access in Brazil: a nation-wide comparison of injecting drug users versus men who have sex with men.

Monica Malta1, Francisco I Bastos, Cosme M F P da Silva, Gerson Fernando Mendes Pereira, Francisca F A Lucena, Maria G P Fonseca, Steffanie A Strathdee.   

Abstract

OBJECTIVE: Brazil accounts for approximately 70% of injection drug users (IDUs) receiving highly active antiretroviral therapy (HAART) in low-income/middle-income countries. We evaluated the impact of HAART availability/access on AIDS-related mortality among IDUs versus men who have sex with men (MSM).
DESIGN: Nation-wide analysis on Brazilian IDU and MSM diagnosed with AIDS in 2000-2006.
METHODS: Four national information systems were linked, and Cox regression was used to assess impact of HAART availability/access on differential AIDS-related mortality.
RESULTS: Among 28,426 patients, 6777 died during 87,792 person-years of follow-up. Compared with MSM, IDU were significantly less likely to be receiving HAART, to have ever had determinations for CD4 or viral load. After controlling for confounders, IDU had a significantly higher risk of death (adjusted hazard ratio: 1.94; 95% confidence interval: 1.84 to 2.05). Among the subset that had at least 1 CD4 and viral load determination, higher risk of death among IDU persisted (hazard ratio: 1.82; 95% confidence interval: 1.58 to 2.11). Nonwhite ethnicity significantly increased this risk, whereas prompt HAART uptake after AIDS diagnosis reduced the risk of death. After controlling for spatially correlated survival data, AIDS-related mortality remained higher in IDU than in MSM.
CONCLUSIONS: Despite free/universal HAART access, differential AIDS-related mortality exists in Brazil. Efforts are needed to identify and eliminate these health disparities.

Entities:  

Mesh:

Year:  2009        PMID: 19675464      PMCID: PMC2787684          DOI: 10.1097/QAI.0b013e3181b31b8a

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  41 in total

1.  Dramatic improvement in survival among adult Brazilian AIDS patients.

Authors:  Jose Ricardo P Marins; Leda F Jamal; Sanny Y Chen; Marilisa B Barros; Esther S Hudes; Aristides A Barbosa; Pedro Chequer; Paulo R Teixeira; Norman Hearst
Journal:  AIDS       Date:  2003-07-25       Impact factor: 4.177

2.  A semiparametric mixture model for analyzing clustered competing risks data.

Authors:  Malay Naskar; Kalyan Das; Joseph G Ibrahim
Journal:  Biometrics       Date:  2005-09       Impact factor: 2.571

Review 3.  The influence of social class on health status: American and British research on health inequalities.

Authors:  O Fein
Journal:  J Gen Intern Med       Date:  1995-10       Impact factor: 5.128

4.  Effects of frailty in survival analysis.

Authors:  O O Aalen
Journal:  Stat Methods Med Res       Date:  1994       Impact factor: 3.021

5.  Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study.

Authors:  S Bassetti; M Battegay; H Furrer; M Rickenbach; M Flepp; L Kaiser; A Telenti; P L Vernazza; E Bernasconi; P Sudre
Journal:  J Acquir Immune Defic Syndr       Date:  1999-06-01       Impact factor: 3.731

6.  High incidence of adverse reactions to initial antiretroviral therapy in Brazil.

Authors:  C A Menezes de Pádua; C C César; P F Bonolo; F A Acurcio; M D C Guimarães
Journal:  Braz J Med Biol Res       Date:  2006-04-03       Impact factor: 2.590

7.  Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Authors:  Cunlin Wang; David Vlahov; Noya Galai; Joseph Bareta; Steffanie A Strathdee; Kenrad E Nelson; Timothy R Sterling
Journal:  J Infect Dis       Date:  2004-08-17       Impact factor: 5.226

8.  Highly active antiretroviral therapy in Brazil: the challenge of universal access in a context of social inequality.

Authors:  Mariana A Hacker; Maya L Petersen; Melissa Enriquez; Francisco I Bastos
Journal:  Rev Panam Salud Publica       Date:  2004-08

9.  Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

Authors:  Evan Wood; Robert S Hogg; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

10.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.

Authors:  Colette Smit; Ronald Geskus; Sarah Walker; Caroline Sabin; Roel Coutinho; Kholoud Porter; Maria Prins
Journal:  AIDS       Date:  2006-03-21       Impact factor: 4.177

View more
  21 in total

1.  Long-term antiretroviral treatment outcomes in seven countries in the Caribbean.

Authors:  Serena P Koenig; Luis A Rodriguez; Courtenay Bartholomew; Alison Edwards; Tracie E Carmichael; Geoffrey Barrow; André Cabié; Robert Hunter; Giselle Vasquez-Mora; Avion Quava-Jones; Nicholas Adomakoh; J Peter Figueroa; Bernard Liautaud; Magaly Torres; Jean W Pape
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

2.  Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy.

Authors:  M-J Milloy; Thomas Kerr; Jane Buxton; Tim Rhodes; Andrea Krusi; Silvia Guillemi; Robert Hogg; Julio Montaner; Evan Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

Review 3.  Adherence to antiretroviral medications among persons who inject drugs in transitional, low and middle income countries: an international systematic review.

Authors:  Jonathan Feelemyer; Don Des Jarlais; Kamyar Arasteh; Anneli Uusküla
Journal:  AIDS Behav       Date:  2015-04

4.  [Survival analysis in people diagnosed with HIV/AIDS in Puerto Rico].

Authors:  Melissa Marzán-Rodríguez; Diego E Zavala Segarra; Juan Carlas Orengo Valverde; Nelson Varas-Díaz; Sandra Miranda De León; Eliseo Acevedo-Díaz
Journal:  Rev Puertoriq Med Salud Publica       Date:  2018

Review 5.  Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention.

Authors:  Steffanie A Strathdee; Steven Shoptaw; Typhanye Penniman Dyer; Vu Minh Quan; Apinun Aramrattana
Journal:  Curr Opin HIV AIDS       Date:  2012-07       Impact factor: 4.283

6.  HIV/AIDS patients' medical and psychosocial needs in the era of HAART: a cross-sectional study among HIV/AIDS patients receiving HAART in Yunnan, China.

Authors:  Yi Wen; Yun Shi; Chengqin Jiang; Roger Detels; Di Wu
Journal:  AIDS Care       Date:  2012-10-15

Review 7.  HIV prevalence among female sex workers, drug users and men who have sex with men in Brazil: a systematic review and meta-analysis.

Authors:  Monica Malta; Monica M F Magnanini; Maeve B Mello; Ana Roberta P Pascom; Yohana Linhares; Francisco I Bastos
Journal:  BMC Public Health       Date:  2010-06-07       Impact factor: 3.295

8.  Poor retention in early care increases risk of mortality in a Brazilian HIV-infected clinical cohort.

Authors:  Daniel S Teixeira da Silva; Paula M Luz; Jordan E Lake; Sandra W Cardoso; Sayonara Ribeiro; Ronaldo I Moreira; Jesse L Clark; Valdilea G Veloso; Beatriz Grinsztejn; Raquel B De Boni
Journal:  AIDS Care       Date:  2016-07-27

9.  Methadone maintenance treatment and mortality in HIV-positive people who inject opioids in China.

Authors:  Yan Zhao; Cynthia X Shi; Jennifer M McGoogan; Keming Rou; Fujie Zhang; Zunyou Wu
Journal:  Bull World Health Organ       Date:  2013-02-01       Impact factor: 9.408

10.  Patients' demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals.

Authors:  Solomon Odafe; Ochanya Idoko; Titilope Badru; Bolatito Aiyenigba; Chiho Suzuki; Hadiza Khamofu; Obinna Onyekwena; Emeka Okechukwu; Kwasi Torpey; Otto N Chabikuli
Journal:  J Int AIDS Soc       Date:  2012-09-18       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.